PolyPeptide Group AGPLYGF 56 EBITDA Margin % is 10.44% as of Dec. 2025, which is 43% below its 10-year median of 18.41. GuruFocus rates PLYGF with a GF Score™ of 56/100 and a GF Value™ of $26.83 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 953 Drug Manufacturers companies, PolyPeptide Group AG ranks worse than 62.85% on this metric.
PolyPeptide Group AG (OTCPK:PLYGF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
PolyPeptide Group AG EBITDA Margin % Related Terms
PolyPeptide Group AG EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for PolyPeptide Group AG's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PLYGF vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PolyPeptide Group AG EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where PolyPeptide Group AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PolyPeptide Group AG (PLYGF) has a EBITDA Margin % of 10.44% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PolyPeptide Group AG and its competitors. This is 43% below median its historical median of 18.41. According to the industry distribution chart, PolyPeptide Group AG ranks #599 out of 953 companies in the Drug Manufacturers industry, placing it in the top 62.9%.
Is PolyPeptide Group AG's EBITDA Margin % too high?
PolyPeptide Group AG's current EBITDA Margin % of 10.44% is 43% below median its 10-year median of 18.41. The Drug Manufacturers industry median EBITDA Margin % is 12.49. PolyPeptide Group AG's value of 10.44% is 16.4% below this industry median. Based on the distribution chart, PolyPeptide Group AG ranks #599 out of 953 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, PolyPeptide Group AG has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PolyPeptide Group AG ranks #599 out of 953 companies for EBITDA Margin %. This places PolyPeptide Group AG in the lower half of its industry. The industry median EBITDA Margin % is 12.49. PolyPeptide Group AG's value of 10.44% is 16.4% below this benchmark. While the company's 10-year median is 18.41 vs. the industry median of 12.49, PolyPeptide Group AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PolyPeptide Group AG's current EBITDA Margin % of 10.44% is 16.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PolyPeptide Group AG and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PolyPeptide Group AG's current EBITDA Margin % is 10.44%, which is 43% below median its own 10-year median of 18.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (PLYGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $26.83, compared to a current price of $43.00 — trading 60.3% above its estimated fair value. The current EBITDA Margin % is 10.44%, which is 43% below median its 10-year median of 18.41 and 16.4% below the Drug Manufacturers industry median of 12.49. PolyPeptide Group AG's overall GF Score™ is 56/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PolyPeptide Group AG (PLYGF), the current EBITDA Margin % is 10.44% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PolyPeptide Group AG (PLYGF) Overvalued in 2026?
Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued.
The current stock price of $43.00 is trading 60.3% above its estimated GF Value™ of $26.83.
GuruFocus considers PolyPeptide Group AG to be Significantly Overvalued.
Key valuation signals for PLYGF:
EBITDA Margin %: 10.44% (43% below median its 10-year median of 18.41)
GF Value™: $26.83 vs. price of $43.00 (60.3% above fair value)
Industry Position: 16.4% below the Drug Manufacturers median (#599 of 953)
No single metric tells the full story. See the PLYGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
56GF Score
Get the complete analysis for PLYGF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLYGF has been successfully added to your 
